Latest levofloxacin Stories

Solithromycin demonstrated enhanced anti-inflammatory response, in vitro CHAPEL HILL, N.C., May 20, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and enhanced...

TAIPEI, Taiwan, May 16, 2013 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they have submitted New Drug Application (NDA) for the oral formulation of nemonoxacin with the Taiwan Food and Drug Administration (TFDA) and China Food and Drug Administration (CFDA). Approval is expected in the first half of 2014. Nemonoxacin is the first pharmaceutical product to fall under the Cross-Strait Cooperation Agreement on Medicine and Public Health Affairs...

CHAPEL HILL, N.C., Dec. 19, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the initiation of its global Phase 3 clinical trial of orally-administered solithromycin, the company's fluoroketolide antibiotic candidate, in patients with community-acquired bacterial pneumonia (CABP). The Phase 3 study is a...

MIAMI, Sept. 10, 2012 /PRNewswire/ -- Nuovo Biologics, LLC announced that Robert G. Savage has joined its Board. Mr. Savage served as Group Vice President and President - General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003. From 1996 through 2001, Mr. Savage served Johnson & Johnson in a variety of roles, most recently as Worldwide Chairman of Johnson and Johnson's Pharmaceutical Group. From 1985 to...

MENLO PARK, Calif., Sept. 7, 2012 /PRNewswire/ -- Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12. The data describe the in vitro and in vivo activity of KPI-10 against a wide range of important gram-negative...

TAIPEI, Taiwan, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhejiang Medicine Company, Limited ("ZMC") today announced that they have signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. TaiGen will be responsible for...

CHAPEL HILL, N.C., May 10, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2012. The company will host a conference call and webcast at 4:30 p.m. EDT, today. "The first quarter of 2012 was a productive period for Cempra," said Prabhavathi Fernandes, Ph.D.,...

The FDA has announced its approval of the antibacterial agent levofloxacin, or “Levaquin,” to treat and prevent the plague. Manufactured by Johnson & Johnson, Levaquin was approved under the FDA’s Animal Efficacy rule which allows results from animal testing to be studied if such tests on humans aren’t ethical or feasible. Why prevent the plague, and why now? Also known as Yersinia pestis, the plague is considered to be a bioterrorism threat. As such, the US government...

CHAPEL HILL, N.C., March 31, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase...

Last month, the California Supreme Court agreed to review a class-action lawsuit over the drug Cipro. Cipro is a brand name for ciprofloxacin, of a class of antibiotic drugs known as fluoroquinolones. Manufactured originally by Bayer, it is used for many types of infections including pneumonia, skin infections, urinary tract infections, bronchitis and joint infections, among others. The lawsuit argues that it was illegal for Bayer to pay a competitor to stay out of the market as part of a...